Management of Menopausal Symptoms

Study Description and Methods

Hormone therapy (HT) has been proven to be the most effective treatment for menopausal symptoms and is an acceptable option in many women up to 59 years of age. However, consideration of other treatment options may be necessary for women who are not able or do not want to take HT. Because of the potential risks of long-term HT use, it is equally important to ensure that women between the ages of 60-65 years stop using HT unless deemed appropriate. Further, breast cancer risk increases with age. Medications to reduce risk for primary breast cancer are recommended for women at increased risk, but use is low. Issues at both sides of this age spectrum (under and over 60 years) are important and require different management strategies. It is important to offer appropriate and individualized treatment options.

This project is designed to evaluate a patient-centered, shared decision making intervention in 12 primary care practices that use an Electronic Health Record (EHR) and have a wireless Internet connection. Tablet computer technology will be integrated into practice workflow and results of health risk appraisal tools (menopause rating scale and breast cancer risk assessment) will be incorporated into the EHR for shared decision making at the point of care. The target audiences for this intervention are primary care providers and staff caring for women ages 45-65 years.

Specific Aims and Objectives

The primary aims of this study are to:

  1. Evaluate the impact of improved information collection and documentation of diagnosis of menopause or postmenopausal symptoms
  2. Assess patient and provider satisfaction with the shared decision making process

Secondary aims will address medication use and communication between patients and providers.


This study will be conducted from January 2014 through December 2015.


Active intervention is currently in progress.

Key Findings and Publications

Please check back at a later date for research results and key findings.

Contact Information

For additional information about this study, please contact:

Robin Liston, MPH
Research Project Manager
AAFP National Research Network
(800) 274-2237, ext. 3175

This study is funded by grants from Pfizer Pharmaceuticals.